Reversing PD-1 Resistance in B16F10 Cells and Recovering Tumour Immunity Using a COX2 Inhibitor

SIMPLE SUMMARY: Some patients develop drug resistance to programmed cell death protein 1/programmed death-ligand 1(PD-1/PD-L1) therapy but the mechanism is unclear. Therefore, the study of drug resistance to PD-1 therapy is quite important. In this sense, we obtained B16F10-R tumours resistant to an...

Descripción completa

Detalles Bibliográficos
Autores principales: Pi, Chenyu, Jing, Ping, Li, Bingyu, Feng, Yan, Xu, Lijun, Xie, Kun, Huang, Tao, Xu, Xiaoqing, Gu, Hua, Fang, Jianmin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9455073/
https://www.ncbi.nlm.nih.gov/pubmed/36077671
http://dx.doi.org/10.3390/cancers14174134

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9455073/
https://www.ncbi.nlm.nih.gov/pubmed/36077671
http://dx.doi.org/10.3390/cancers14174134

Ejemplares similares